Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Perrigo’s global self-care operations means sorting through FDA correspondence, European labelling rules, and dozens of product-recall footnotes scattered across hundreds of pages. Whether you’re checking how inflation squeezed infant-formula margins or comparing store-brand versus branded revenue, the raw SEC data can feel overwhelming.
Stock Titan distills every Perrigo annual report 10-K simplified, each Perrigo quarterly earnings report 10-Q filing, and any Perrigo 8-K material events explained into concise, plain-English highlights. Our AI maps line items to the questions professionals actually ask—“What did Perrigo spend on quality remediation?” or “How did international currency swings hit EPS?”—and flags risk language automatically. Receive Perrigo Form 4 insider transactions real-time, monitor Perrigo executive stock transactions Form 4, and review the Perrigo proxy statement executive compensation without manual searches. For professionals intent on understanding Perrigo SEC documents with AI, our platform layers contextual definitions over GAAP terms and links directly to source exhibits.
Looking for Perrigo insider trading Form 4 transactions ahead of a product launch? Need a quick Perrigo earnings report filing analysis that separates North American from international self-care trends? Or simply want Perrigo SEC filings explained simply so you can brief clients in minutes? Every document arrives within seconds of hitting EDGAR, paired with AI-powered summaries, key-metric tables, and historical comparisons. Spend more time assessing how Perrigo’s affordable OTC strategy drives cash flow and less time sifting through PDFs.
Perrigo Company plc reported an insider equity award to one of its directors. On December 12, 2025, the director acquired 2,140 restricted stock units, each representing a contingent right to receive one ordinary share.
The restricted stock units are scheduled to vest on December 12, 2026. Following this grant, the director beneficially owns 41,160.148 ordinary shares on a direct basis.
Perrigo Company plc director Geoffrey Parker reported an equity award and his updated holdings in the company’s ordinary shares. On 12/12/2025, he received 2,140 Restricted Stock Units, each representing a contingent right to receive one Perrigo ordinary share, scheduled to vest on 12 December 2026.
After this award, he beneficially owns 28,912 ordinary shares directly, 25,879 ordinary shares through a revocable trust, 17,375 ordinary shares in a Roth IRA, and 2,140 Restricted Stock Units as a derivative security position.
Perrigo (PRGO): T. Rowe Price Associates, Inc. filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 16,920,302 shares of common stock, representing 12.3% of the class as of 09/30/2025.
The filer reports sole voting power over 16,856,660 shares and sole dispositive power over 16,920,302 shares, with no shared voting or dispositive power. T. Rowe Price files as an investment adviser and states the securities were acquired and are held in the ordinary course, not to change or influence control.
Within the reported holdings, T. Rowe Price Mid-Cap Value Fund has an interest in 9,190,014 shares, equal to 6.7% of the class.
Perrigo Co plc (PRGO) reported an insider transaction by director Geoffrey Parker. On 11/12/2025, Parker purchased 7,500 ordinary shares at a weighted average price of $14.18 per share, executed in multiple trades ranging from $14.16 to $14.20. The shares were acquired indirectly via a Roth IRA.
Following the transaction, Parker beneficially owned 17,375 shares indirectly (IRA), 28,912 shares directly, and 25,879 shares indirectly through a revocable trust where he and Jill Parker serve as trustees.
Perrigo Company plc reported third-quarter 2025 results. Net sales were $1,043.3 million versus $1,087.5 million a year ago, while operating income was $72.6 million versus $80.4 million. Net income was $7.5 million compared with a loss of $21.0 million in the prior-year quarter. Interest expense improved to $40.6 million from $57.6 million.
Year to date, sales were $3,143.5 million versus $3,235.1 million, with operating income of $164.9 million (versus a slight loss last year) and a net loss of $7.3 million (versus $127.3 million). Cash from operating activities was $63.1 million. Cash stood at $432.1 million and long‑term debt at $3,608.1 million. Inventories were $1,227.0 million.
The company agreed to sell its Dermacosmetics branded business for up to €327 million, including €300 million upfront and up to €27 million in earn‑outs, subject to regulatory and works council approvals, with closing expected in the first quarter of 2026. Related assets and liabilities held for sale were $280.5 million and $37.4 million, respectively. Shares outstanding were 137,624,009 as of October 31, 2025.
Perrigo Company plc (PRGO) furnished an 8-K announcing two items: it released earnings for the third quarter ended September 27, 2025 (Item 2.02), and it is initiating a strategic review of its infant formula business (Item 7.01). Both related press releases were furnished as Exhibits 99.1 and 99.2 on November 5, 2025.
The company highlighted use of non-GAAP measures to evaluate ongoing operating trends, comparability, and performance assessment. For recent periods, adjustments included amortization of acquired intangibles, unusual litigation, restructuring and termination benefits, impairment charges, infant formula remediation, divestiture gains or losses, foreign currency translation, non-GAAP tax adjustments, and other items. Management also references constant currency net sales and free cash flow among the metrics it reviews.
The earnings and strategic review press releases are expressly furnished, not filed, limiting their incorporation by reference under the Exchange Act and Securities Act.
Perrigo Company plc (PRGO) reporting person Matthew John Winterman received grants of restricted stock units on 07/08/2025 totaling 36,846 units: 31,319 RSUs and 5,527 RSUs. Each RSU represents a contingent right to receive one ordinary share. The filing shows no prior beneficial ownership before these reported transactions and records direct ownership of the 31,319 and 5,527 ordinary shares following the awards. The 31,319 RSUs include a vesting provision noted in the filing as vesting in two equal annual installments beginning July 8, 2026, while the 5,527 RSUs vest in three equal annual installments beginning July 8, 2026. The form is signed by an attorney-in-fact for Mr. Winterman and was filed on 08/22/2025.
Geoffrey M. Parker, a director of Perrigo Company plc (PRGO), reported transactions dated 09/12/2025. He disposed of 28,912 ordinary shares and received 1,263 Restricted Stock Units that vest on 12 September 2026. After the reported transactions he beneficially owned 25,879 ordinary shares directly, plus 9,875 shares via a revocable trust and 9,875 shares via a Roth IRA as disclosed. The Form 4 was signed by an attorney-in-fact on 09/15/2025. Explanations clarify that each RSU converts to one ordinary share on vesting.
Bradley A. Alford, a director of Perrigo Company plc (PRGO), reported a sale and a grant on Form 4. The filing shows a disposition of 41,160.148 ordinary shares on 09/12/2025. The filing also reports acquisition of 1,263 Restricted Stock Units (RSUs) on 09/12/2025, each representing a contingent right to one ordinary share, with vesting on 12 September 2026. The RSUs are held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Alford on 09/15/2025. The document does not state a sale price, remaining total ordinary shares owned after the sale, or the reason for the transactions.
Insider transactions at Perrigo Company plc (PRGO): An executive (EVP & CBDO) received 7,701 Restricted Stock Units that convert one-for-one into ordinary shares and were reported as acquired, while 2,784 ordinary shares were sold. After these transactions the reporting person beneficially owned 4,917 ordinary shares. The RSUs vest in two equal annual installments beginning on the report's transaction date, so further share delivery will occur over the next year as vesting conditions are met. The mix of a granted/vested equity award and a contemporaneous sale of company stock is consistent with routine executive compensation and portfolio management.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
